Antibody data
- Antibody Data
- Antigen structure
- References [6]
- Comments [0]
- Validations
- Western blot [2]
- Flow cytometry [1]
- Other assay [4]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 44-1052 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Phospho-VEGF Receptor 2 (Tyr1214) Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µL
- Storage
- -20°C
Submitted references Blockade of insulin receptor substrate-1 inhibits biological behavior of choroidal endothelial cells.
Epidermal-specific deletion of TC-PTP promotes UVB-induced epidermal cell survival through the regulation of Flk-1/JNK signaling.
The docking protein FRS2α is a critical regulator of VEGF receptors signaling.
Microtubules coordinate VEGFR2 signaling and sorting.
The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib.
Synthetic heparan sulfate oligosaccharides inhibit endothelial cell functions essential for angiogenesis.
Qian YY, Wu HY, Liu GQ, Ren C, Lu PR, Zhang XG
International journal of ophthalmology 2019;12(9):1386-1394
International journal of ophthalmology 2019;12(9):1386-1394
Epidermal-specific deletion of TC-PTP promotes UVB-induced epidermal cell survival through the regulation of Flk-1/JNK signaling.
Baek M, Kim M, Lim JS, Morales LD, Hernandez J, Mummidi S, Williams-Blangero S, Jang IS, Tsin AT, Kim DJ
Cell death & disease 2018 Jun 28;9(7):730
Cell death & disease 2018 Jun 28;9(7):730
The docking protein FRS2α is a critical regulator of VEGF receptors signaling.
Chen PY, Qin L, Zhuang ZW, Tellides G, Lax I, Schlessinger J, Simons M
Proceedings of the National Academy of Sciences of the United States of America 2014 Apr 15;111(15):5514-9
Proceedings of the National Academy of Sciences of the United States of America 2014 Apr 15;111(15):5514-9
Microtubules coordinate VEGFR2 signaling and sorting.
Czeisler C, Mikawa T
PloS one 2013;8(9):e75833
PloS one 2013;8(9):e75833
The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib.
Mao WF, Shao MH, Gao PT, Ma J, Li HJ, Li GL, Han BH, Yuan CG
Acta pharmacologica Sinica 2012 Oct;33(10):1311-8
Acta pharmacologica Sinica 2012 Oct;33(10):1311-8
Synthetic heparan sulfate oligosaccharides inhibit endothelial cell functions essential for angiogenesis.
Cole CL, Hansen SU, Baráth M, Rushton G, Gardiner JM, Avizienyte E, Jayson GC
PloS one 2010 Jul 21;5(7):e11644
PloS one 2010 Jul 21;5(7):e11644
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Peptide Competition and Stimulation: Extracts prepared from CSF-1-stimulated (1-4, 6) or unstimulated (5) PAE cells transfected with a chimeric CSF-1/VEGFR2 receptor (see Positive Controls Used section above for full description) were resolved by SDS-PAGE.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis was performed on whole cell extracts (30 µg lysate) of HT-29 (Lane 1), HT-29 Serum Starved followed by treatment for 10 minutes with 100 ng/mL of SCF (Lane 2), CaCo-2 (Lane 3) and CaCo-2 Serum Starved followed by treatment for 10 minutes with 100 ng/mL of SCF (Lane 4). The blots were probed with Anti-VEGF Receptor 2 (pY1214) Rabbit Polyclonal Antibody (Product # 44-1052, 1:1000 dilution) and detected by chemiluminescence using Goat anti-Rabbit IgG (H+L) Secondary Antibody, HRP conjugate (Product # G-21234, 1:5000 dilution). A 151 kDa band corresponding to VEGF Receptor 2 (pY1214) was enhanced upon treatment across the cell lines tested. Known quantity of protein samples were electrophoresed using Novex® NuPAGE®10 % Bis-Tris gel (Product # NP0301BOX), XCell SureLock™ Electrophoresis System (Product # EI0002) and Novex® Sharp Pre-Stained Protein Standard (Product # LC5800). Resolved proteins were then transferred onto a nitrocellulose membrane with overnight wet transfer system. The membrane was probed with the relevant primary and secondary Antibody following blocking with 5 % skimmed milk. Chemiluminescent detection was performed using Pierce™ ECL Western Blotting Substrate (Product # 32106).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Flow cytometry analysis of VEGF Receptor 2 [pTyr1214] was done on HUVEC-C cells treated with VEGF (25ng/mL, 5 minutes). Cells were fixed with 70% ethanol for 10 minutes, permeabilized with 0.25% Triton™ X-100 for 20 minutes, and blocked with 5% BSA for 30 minutes at room temperature. Cells were labeled with VEGF Receptor 2 [pTyr1214] Rabbit Polyclonal Antibody (441052, red histogram) or with rabbit isotype control (yellow histogram) at 3-5 ug/million cells in 2.5% BSA. After incubation at room temperature for 2 hours, the cells were labeled with Alexa Fluor® 488 Goat Anti-Rabbit Secondary Antibody (A11008) at a dilution of 1:400 for 30 minutes at room temperature. The representative 10,000 cells were acquired and analyzed for each sample using an Attune® Acoustic Focusing Cytometer. The purple histogram represents unstained control cells and the green histogram represents no-primary-antibody control.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Antibody specificity is demonstrated by Peptide Array. Western blotting Western blotting analysis of Phospho-VEGF Receptor 2 (Tyr1214) using anti Phospho-VEGF Receptor 2 (Tyr1214) Polyclonal Antibody (Product # 44-1052) shows loss of signal with the specific peptide and not with other relevant peptides.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 7 Oligosaccharides inhibit FGF2- and VEGF 165 -induced receptor activation and signalling. ( A ) Serum-starved HUVECs were stimulated with FGF2 for 10 min in the absence or presence of increasing concentrations of indicated oligosaccharides. Phosphorylated FRS2 and Erk were detected by Western blotting. Equal protein loading was monitored by probing with the anti-GAPDH antibody. The values below each blot represent an average normalized fold change in the intensities of bands as compared to the bands corresponding to FGF2 stimulated cells in the absence of oligosaccharides. The normalized fold change was derived from three independent experiments. ( B ) Fold change of phosphorylated FRS2 and Erk levels in FGF2 treated cells in the presence of oligosaccharides as compared to the FGF2 stimulated cells without oligosaccharide treatment. Amount of phosphorylated FRS2 and Erk as determined by densitometric evaluation was normalized against corresponding GAPDH levels. Values are the mean +- SEM (n = 3). *, P
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 6 FGF2- and VEGF 165 -induced peripheral accumulation of activated FAK and F-actin is inhibited by 2SNS 12-mer oligosaccharide. ( A ) Lack of peripheral accumulation of FAK phosphorylated on tyrosine 397 and F-actin in serum-starved HUVECs. Cells were co-stained with anti-phospho-FAK (pTyr397) antibody (left image) and phalloidin-AlexaFluor568 (middle image). Merged view is represented in the right image. Scale bar, 75 um. ( B-C ) Peripheral FAK phosphorylated at tyrosine 397 and F-actin are detected after 10 min stimulation with FGF2 ( B , upper images) or VEGF 165 ( C , upper images). 12-mer 2SNS oligosaccharide prevents peripheral localization of phosphorylated FAK and F-actin in response to FGF2 ( B , lower images) or VEGF 165 ( C , lower images). Merged images are presented in the right panel. Scale bars, 75 um. ( D ) Percentage of cells with peripheral FAK phosphorylated on tyrosine 397 in unstimulated (0.1% FBS) or FGF2 or VEGF 165 stimulated cells in the absence or presence of 12-mer 2SNS or 12-mer 2S is shown as the mean +-SD (n = 3). *, P